Tempest Therapeutics Files 8-K on Leadership and Compensation Changes
Ticker: TPST · Form: 8-K · Filed: Jun 6, 2025 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Jun 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, corporate-governance
Related Tickers: TPST
TL;DR
Tempest Therapeutics (TPST) filed an 8-K today covering board and exec comp changes.
AI Summary
On June 5, 2025, Tempest Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in corporate governance and potential adjustments to how key personnel are compensated.
Why It Matters
Changes in board composition and executive compensation can signal strategic shifts or financial adjustments within the company, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty about the company's future direction and financial stability.
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Registrant
- June 5, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 001-35890 (identifier) — Commission File Number
- 45-1472564 (identifier) — IRS Employer Identification No.
- Millendo Therapeutics, Inc. (company) — Former Company Name
- OvaScience, Inc. (company) — Former Company Name
FAQ
What specific changes were made to the board of directors?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors" as an item of report, suggesting changes in board composition, though specific names are not detailed in this excerpt.
What is the nature of the changes in compensatory arrangements?
The filing lists "Compensatory Arrangements of Certain Officers" as an item of report, indicating that there have been adjustments or new agreements related to executive compensation.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated June 5, 2025, which is also the date of the report.
What is Tempest Therapeutics, Inc.'s primary industry?
Tempest Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].
Has Tempest Therapeutics, Inc. operated under different names previously?
Yes, the company was formerly known as Millendo Therapeutics, Inc. (name change effective December 7, 2018) and prior to that, OvaScience, Inc. (name change effective March 8, 2012).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 6, 2025 regarding Tempest Therapeutics, Inc. (TPST).